What's Happening?
A large Italian study has revealed a significant association between discontinuing Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a higher incidence of major cardiovascular events and all-cause mortality in individuals with type 2 diabetes.
The retrospective cohort study, which analyzed data from 301 diabetes clinics in Italy between 2004 and 2024, found that patients who stopped GLP-1RA therapy experienced approximately twice the incidence of a composite endpoint of nonfatal heart attack, nonfatal stroke, or death from any cause, compared to those who continued treatment. Furthermore, mortality rates were nearly fivefold higher after GLP-1RA discontinuation. This occurs despite GLP-1RAs being known for their substantial benefits in cardiovascular and renal health, alongside their glucose- and weight-lowering effects. Discontinuation rates for GLP-1RAs are high, ranging from 20% to 50% within the first year, often due to gastrointestinal side effects, perceived inadequate effects, high costs, and other concerns. The study included individuals with type 2 diabetes who had no prior history of major cardiovascular events.
Why It's Important?
This study highlights a critical public health concern regarding the long-term management of type 2 diabetes and cardiovascular risk. The findings suggest that the benefits of GLP-1RAs may extend beyond their direct impact on conventional risk factors like blood sugar, lipids, and blood pressure, which showed only modest changes after treatment cessation. The increased risk of cardiovascular events and mortality following discontinuation could place a significant burden on healthcare systems and patient outcomes. For pharmaceutical companies, these findings underscore the importance of developing GLP-1RAs with improved tolerability and exploring strategies to enhance patient adherence. Clinicians may need to re-evaluate the risks and benefits of discontinuing these medications, potentially leading to more cautious approaches and increased patient education on the importance of continuous therapy. Patients with type 2 diabetes who are on GLP-1RAs, or considering them, will need to be fully informed about these potential risks associated with stopping treatment.
What's Next?
The study's authors suggest that more flexible dose-escalation regimens for GLP-1RAs could improve tolerability and reduce discontinuation rates, which may be a focus for future pharmaceutical development and clinical practice guidelines. Further research is needed to confirm these findings in specifically designed prospective studies and to explore the underlying mechanisms behind the increased risk after discontinuation. It will be crucial to investigate whether starting and then stopping GLP-1RA therapy carries a higher risk than never using these medications at all. Healthcare providers may begin to emphasize the importance of long-term adherence to GLP-1RA therapy more strongly, and patient support programs could be developed to help manage side effects and improve persistence. Policy discussions might also arise regarding the accessibility and affordability of these medications to ensure continuous treatment for patients who benefit from them.
Beyond the Headlines
The study raises profound questions about the full scope of GLP-1RA benefits and the potential for unmeasured health factors to influence outcomes. The significant increase in mortality rates after discontinuation, which was larger than the cardiovascular benefits observed in earlier randomized trials, suggests that other underlying health issues or the development of frailty or malignancies might contribute to the decision to discontinue treatment, indicating possible reverse causation. This complexity means that simply attributing the increased risk solely to the absence of the drug's protective effects might be an oversimplification. The findings also highlight the challenges of observational studies in establishing causality and the need for comprehensive data collection, including socioeconomic factors and specific reasons for drug discontinuation, to fully understand the interplay of various factors affecting patient health outcomes. This could lead to a re-evaluation of how treatment discontinuation is studied and interpreted in chronic disease management.













